Hence why I asked as I did do DD
Estimated quarters of funding available (item 8.4 divided by item 8.1) 7.03
• Cash balance of $11.5 million at 31 December 2023.1
The increase in R&D spend for the December quarter ($4.97 million) compared to the September quarter
($3.23 million) reflected increased clinical trial activity as the XanaMIA Phase 2b AD trial commenced
investigational site activation.
The Company received an R&D tax incentive refund from the Australian Tax Office for the 2023 financial year
of approximately $4.79 million on 28 November 2023.
So they've got $11.5m at the start of the '23, and spending 3-4m per Q less rebates (half?). Say net 2-2.5m/Q.
What am I missing?
I can't see any CR based shorting that normally aligns to a discounted CR etc Be nice if the SP touched 3c or lower buttheir loan accounts ... 25% vesting after 12 months, and remainder monthly for the next 12 months ... not so sure they'll want to discount for a raise accordingly.
1 01/12/23 Dr Nicki Vasquez Issued 5,500,000 .031 2 01/12/23 Dr Nicki Vasquez Issued 5,500,000 $0.031 $171,875 Issued under employee share plan 1,875 Issued under employee share plan 3 01/12/23 Mr Malcolm John McComas Issued 4,500,000 $0.031 $140,625 Issued under employee share plan 4 01/12/23 Dr George Morstyn Issued 4,500,000 $0.031 $140,625 Issued under employee share plan 5 01/12/23 Dr Steven Gourlay Issued 20,000,000 $0.031 $625,000 Issued under employee share plan 6 01/12/23 Dr Geoffrey E.D Brooke Issued 12,000,000 $0.031 $375,000 Issued under employee share plan
Just an observation.
- Forums
- ASX - By Stock
- ACW
- Ann: Actinogen announces $10 million rights offer
Ann: Actinogen announces $10 million rights offer, page-44
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACW (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.001(3.23%) |
Mkt cap ! $85.85M |
Open | High | Low | Value | Volume |
3.1¢ | 3.3¢ | 3.1¢ | $63.27K | 1.981M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 36560 | 3.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.2¢ | 234980 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 36560 | 0.031 |
5 | 2325290 | 0.030 |
3 | 559543 | 0.029 |
5 | 2275632 | 0.028 |
2 | 165275 | 0.027 |
Price($) | Vol. | No. |
---|---|---|
0.032 | 234980 | 1 |
0.033 | 1793806 | 5 |
0.034 | 483560 | 2 |
0.035 | 464913 | 3 |
0.036 | 326662 | 3 |
Last trade - 15.54pm 20/06/2024 (20 minute delay) ? |
Featured News
ACW (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online